Medications

Wegovy vs Zepbound: Which Weight-Loss Shot Does What?

Wegovy and Zepbound are the two leading FDA-approved weekly injections for weight management - they use different molecules, carry different extra indications, come in different devices and are priced very differently.

Last verified September 14, 2026·11 sources cited·Wegovy Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

If you are choosing between the two biggest weekly weight-loss injections in the United States, the honest summary is this: Zepbound has produced more weight loss in the one trial that compared them directly, Wegovy has the broader label, and the two are priced through completely different channels.

Here is the detail behind each of those claims.

What is in each one?

Wegovy contains semaglutide, a GLP-1 receptor agonist. It was approved for chronic weight management on June 4, 2021 [3].

Zepbound contains tirzepatide, which activates two receptors, GIP and GLP-1. It was approved on November 8, 2023 [4].

Same drug family, different molecules. Wegovy’s doses run 0.25 to 7.2 mg; Zepbound’s run 2.5 to 15 mg. Those numbers do not translate to each other.

What is each one approved for?

This is where the two products genuinely diverge.

Wegovy injection [1]:

Reducing excess body weight and maintaining weight reduction long term in adults and patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition
Reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (approved March 8, 2024)
Treating noncirrhotic MASH with moderate to advanced liver fibrosis in adults, under accelerated approval granted August 15, 2025 [6]

Zepbound [2]:

Reducing excess body weight and maintaining weight reduction long term in adults with obesity or adults with overweight plus at least one weight-related condition
Treating moderate to severe obstructive sleep apnea in adults with obesity (approved December 20, 2024) [5]

So Wegovy covers heart outcomes and a liver disease. Zepbound covers sleep apnea. Wegovy reaches adolescents; Zepbound is adults only.

For many people that list settles the question before weight loss numbers ever enter the conversation.

How much weight do people lose on each?

SURMOUNT-5 was the head-to-head trial. Complete results published in the New England Journal of Medicine in May 2025 showed Zepbound producing superior weight loss compared with Wegovy in adults with obesity [4].

The individual trials give a sense of the range:

Wegovy 2.4 mg: average weight loss in the high teens across its registration trials
Wegovy HD 7.2 mg: about 20.7% at 72 weeks among people who stayed on treatment in STEP UP (18.8% counting everyone regardless of adherence), with 31.2% losing 25% or more of their body weight versus 15.3% on 2.4 mg [7]
Zepbound 15 mg: an average of 48 pounds in SURMOUNT-1 in adults without type 2 diabetes; Zepbound 5 mg averaged 34 pounds versus 7 pounds on placebo [4]
Zepbound in adults with type 2 diabetes (SURMOUNT-2): 15.7% at 15 mg and 13.4% at 10 mg, versus 3.3% on placebo [4]

One important caveat: SURMOUNT-5 compared Zepbound against Wegovy 2.4 mg, the highest Wegovy dose available when that trial ran. Wegovy HD 7.2 mg was not approved until March 2026, and no head-to-head trial has tested it against tirzepatide.

What do the dosing schedules look like?

Wegovy uses a fixed 16-week escalation [1]:

Weeks	Dose
1-4	0.25 mg
5-8	0.5 mg
9-12	1 mg
13-16	1.7 mg
17 and onward	2.4 mg (recommended) or 1.7 mg

For adults who tolerate 2.4 mg for at least four weeks and need more weight reduction, the label allows going up to a maximum of 7.2 mg [1].

Zepbound uses a step-up-as-needed approach [2]:

Step	Dose
Weeks 1-4	2.5 mg (initiation only, not a maintenance dose)
Each increase, after at least 4 weeks	+2.5 mg
Maintenance for weight	5, 10 or 15 mg
Maintenance for sleep apnea	10 or 15 mg
Maximum	15 mg

Both labels tell prescribers to consider treatment response and tolerability when picking a maintenance dose, and both say not to combine their product with another GLP-1 receptor agonist [1][2].

Missed doses are handled differently. Wegovy’s label says if the next dose is more than two days away, take the missed dose as soon as possible; if less than two days away, skip it. If two or more consecutive doses are missed, the label says to restart escalation at a lower dose [1].

What devices do they come in?

Wegovy [1]:

Single-dose prefilled pen, four per carton, in six color-coded strengths including Wegovy HD 7.2 mg. The needle is hidden and built in, with no priming and nothing to attach.
Single-dose prefilled syringe with an integrated needle, four per carton, approved in May 2026. Novo Nordisk’s own consumer site said these were not yet available at pharmacies as of 2026.
Wegovy FlexTouch, a single-patient-use multi-dose pen holding four weekly 2.4 mg doses in one device. It uses separate screw-on needles and the label carries a specific warning never to share it between patients.

Zepbound [2]:

Single-dose prefilled pen, four per carton
Single-dose vial, sold in 1-packs and 4-packs, exclusively through LillyDirect and self-pay only
Multi-dose vial holding four doses
Single-patient-use KwikPen holding four weekly doses, available since February 23, 2026 [11], and sold at self-pay prices through major pharmacies nationwide as well as LillyDirect since March 13, 2026 [13]

Vials require you to draw the dose with a separate needle and syringe. KwikPens require separate pen needles. Wegovy’s single-dose pen requires neither.

What do they cost?

The two companies sell through their own channels at very different structures.

Wegovy, through NovoCare Pharmacy and the savings offer [9]:

Product	Self-pay per month
0.25 or 0.5 mg, first 2 fills (new patients, through Dec 31 2026)	$199
Any standard dose after the intro	$349
Wegovy HD 7.2 mg	$399

One month is one carton of four pens. Commercially insured patients may pay as little as $25 a month, capped at $100 in savings. Government beneficiaries are excluded.

Novo Nordisk also runs a multi-month subscription through telehealth partners. Its own launch announcement gives the Wegovy pen tiers as $329 a month on a three-month plan, $299 on six months and $249 on twelve months, and the Wegovy pill tiers as $289, $269 and $249. These are self-pay subscription tiers rather than a single price, telehealth platforms may charge their own consultation or membership fees on top, and Novo states that limited-time offers are separate and not included.

Zepbound, through LillyDirect [8]:

Dose	Self-pay per month (vial or KwikPen)
2.5 mg	$299
5 mg	$399
7.5 mg	$449 with a refill inside 45 days, otherwise $499
10, 12.5, 15 mg	$449 with a refill inside 45 days, otherwise $699

A month is 28 days and either four single-dose vials or one KwikPen. Zepbound single-dose pens go through insurance, where eligible commercially insured patients may pay as little as $25 a month for up to a three-month prescription.

Two things to note. LillyDirect’s lower prices depend on refilling within 45 days, so a gap in treatment can push the price up sharply. And both companies’ self-pay routes exclude insurance and government benefits entirely.

What about Medicare and the federal pricing deal?

Under the November 2025 agreement between the White House, Eli Lilly and Novo Nordisk, injectable Ozempic, Wegovy, Mounjaro and Zepbound were priced at $245 a month for Medicare and state Medicaid programs, and Medicare began covering Wegovy and Zepbound for people with obesity and at least one related condition for the first time.

Separately, CMS launched the Medicare GLP-1 Bridge demonstration on July 1, 2026, giving eligible Part D enrollees access to certain GLP-1 medications for $50 a month through December 31, 2027 [10]. Both manufacturers point patients to it, and both require a prior authorization request from the prescriber.

Do the side effects differ?

Broadly, no. Both are dominated by gastrointestinal effects: nausea, diarrhea, vomiting, constipation and stomach pain. Zepbound’s label also lists dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, belching, hair loss and heartburn among common reactions [2]. Wegovy’s lists headache, fatigue, dizziness, bloating, belching, gas, heartburn and nasal or throat symptoms [1].

Both carry the same boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2 [1][2].

A few label-level differences are worth knowing:

Wegovy HD 7.2 mg was associated with altered skin sensation, including sensitive skin, tingling and numbness, in about 22% of STEP UP participants versus 6% on 2.4 mg and 0.3% on placebo [7].
Both labels dropped the Suicidal Behavior and Ideation warning in 2026. On January 13, 2026 FDA issued a Drug Safety Communication saying a review of 91 placebo-controlled trials covering 107,910 participants found no increased risk, and asked the manufacturers of Saxenda, Wegovy and Zepbound to remove the warning [12]. The Wegovy label’s Recent Major Changes section records the removal as 01/2026; Zepbound’s records it as 02/2026 [1][2].
In October 2025 a severe gastrointestinal adverse reactions warning was added to the semaglutide labels [1].

Both labels warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, dehydration leading to kidney injury, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, and the risk of food or liquid entering the lungs during anesthesia or deep sedation.

How should you think about choosing?

Rather than chasing the bigger average number, most people get further with these questions:

Do you have another condition one of them treats? Established heart disease points toward Wegovy’s cardiovascular indication. Diagnosed sleep apnea points toward Zepbound. MASH with fibrosis points toward Wegovy.
Is the patient under 18? Only Wegovy is approved from age 12.
What does your insurance cover, and is there a prior authorization? Coverage differences dwarf list-price differences for most people.
Do you want to avoid handling needles? The Wegovy single-dose pen has a hidden built-in needle. Zepbound vials need a syringe.
Can you commit to refilling on time? LillyDirect’s best Zepbound prices depend on a 45-day refill.
How did you tolerate escalation before? Both labels allow slowing down or stepping back if side effects are hard to manage - that is a conversation with your prescriber, not a decision to make alone.

Sources

This article is general information, not medical advice. Talk to a healthcare provider about which medicine, if any, is appropriate for you.

Questions people ask

Which is better, Wegovy or Zepbound?

In SURMOUNT-5, the head-to-head trial published in the New England Journal of Medicine in May 2025, Zepbound showed superior weight loss compared with Wegovy. But the labels differ in ways that can matter more than average weight loss: only Zepbound is approved for obstructive sleep apnea, and only Wegovy is approved for cardiovascular risk reduction and for MASH with liver fibrosis. This is a decision for you and a healthcare provider.

How much does each one cost without insurance?

Through NovoCare Pharmacy, Wegovy pens are $349 a month at standard doses and $399 for Wegovy HD 7.2 mg, with a $199 introductory price for the first two fills of the two starting doses for new patients through December 31, 2026 (verified 2026-09-14). Through LillyDirect, Zepbound vials and KwikPens are $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 through 15 mg when refilled within 45 days, rising to $499 for 7.5 mg or $699 for 10, 12.5 and 15 mg without that refill.

Are Wegovy and Zepbound the same drug?

No. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which activates both the GIP and GLP-1 receptors. The doses are not comparable and there is no official conversion between them.

Can you switch from Wegovy to Zepbound?

Some people do, but both labels say not to use their product alongside another GLP-1 receptor agonist, so a switch means stopping one and starting the other. Zepbound's label directs starting at 2.5 mg once weekly regardless of what dose you were on before. Only a prescriber can decide whether and how to switch.

Which one is approved for sleep apnea?

Zepbound. FDA approved it on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, at maintenance doses of 10 or 15 mg once weekly. Wegovy is not approved for sleep apnea.

Which one is approved for fatty liver disease?

Wegovy. In August 2025 FDA granted accelerated approval for Wegovy injection 2.4 mg to treat noncirrhotic MASH with moderate to advanced liver fibrosis in adults. Zepbound does not carry a liver indication.

Can teenagers take either one?

Wegovy injection is approved for chronic weight management in patients aged 12 and older with obesity. Zepbound is approved for adults only.

Does Medicare cover either of them?

Under the November 2025 federal pricing agreement, Medicare began covering Wegovy and Zepbound for people with obesity and at least one related condition. Eligible Medicare Part D enrollees can get certain GLP-1 medications for $50 a month through the CMS Medicare GLP-1 Bridge demonstration, which runs from July 1, 2026 through December 31, 2027.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.